This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Bone Therapeutics Management

Management criteria checks 4/4

Key information

Miguel Forte

Chief executive officer

€339.1k

Total compensation

CEO salary percentage	94.2%
CEO tenure	3.8yrs
CEO ownership	n/a
Management average tenure	2.2yrs
Board average tenure	3yrs

Recent management updates

Recent updates

Is Bone Therapeutics (EBR:BOTHE) A Risky Investment?

May 26

What Type Of Returns Would Bone Therapeutics'(EBR:BOTHE) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Dec 16

CEO Compensation Analysis

How has Miguel Forte's remuneration changed compared to Bone Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2022	n/a	n/a	-€10m
Mar 31 2022	n/a	n/a	-€11m
Dec 31 2021	€339k	€319k	-€13m
Sep 30 2021	n/a	n/a	-€13m
Jun 30 2021	n/a	n/a	-€14m
Mar 31 2021	n/a	n/a	-€15m
Dec 31 2020	€432k	€300k	-€16m

Compensation vs Market: Miguel's total compensation ($USD335.14K) is below average for companies of similar size in the Belgian market ($USD492.28K).

Compensation vs Earnings: Miguel's compensation has been consistent with company performance over the past year.

CEO

Miguel Forte (62 yo)

3.8yrs

Tenure

€339,127

Compensation

Dr. Miguel Forte, M.D., Ph D., serves as Chief Executive Officer and Executive Director at Bone Therapeutics SA since December 2019 and 2020 respectively and serves as its Managing Director. He serves as D...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Miguel Forte	CEO, MD & Executive Director	3.8yrs	€339.13k	no data
Anne-Sophie Lebrun	Chief Operations Officer	2.2yrs	no data	no data
Anthony Ting	Chief Scientific Officer	1.5yrs	no data	no data
Gunther De Backer	Head of Corporate Communications & Investor Relations	no data	no data	no data
Valerie Chapelle	Interim HR Director	no data	no data	no data
Stefanos Theoharis	Chief Business Officer	2.6yrs	no data	no data
Anne Leselbaum	Chief Medical Officer	1.2yrs	no data	no data
Ching Choi	Business Development Manager	no data	no data	no data

2.2yrs

Average Tenure

56yo

Average Age

Experienced Management: BOTHE's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Miguel Forte	CEO, MD & Executive Director	2.8yrs	€339.13k	no data
Claudia D'Augusta	Independent Director	4.5yrs	€30.00k	no data
Frank Barry	Member of Scientific Advisory Board	less than a year	no data	no data
Baron Stephenne	Independent Chairman of the Board	4.7yrs	€50.00k	no data
Damian Marron	Independent Director	5.3yrs	€25.00k	no data
Richard Maziarz	Member of Scientific Advisory Board	less than a year	no data	no data
Jean-Paul Prieels	Independent Director	7.6yrs	€25.00k	no data
Jean-Luc Vandebroek	Non-Executive Director	4.3yrs	no data	no data
Gloria Matthews	Independent Director	3.3yrs	€20.00k	no data
Massimo Dominici	Chair of Scientific Advisory Board	less than a year	no data	no data
Patricia Rocco	Member of Scientific Advisory Board	less than a year	no data	no data
Robert Deans	Member of Scientific Advisory Board	less than a year	no data	no data

3.0yrs

Average Tenure

56yo

Average Age

Experienced Board: BOTHE's board of directors are considered experienced (3 years average tenure).

This company is no longer active

Bone Therapeutics Management

Management criteria checks 4/4

Key information

Recent management updates

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

First half 2022 earnings released: €0.15 loss per share (vs €0.37 loss in 1H 2021)

Bone Therapeutics SA Optimizes Statistical Analysis and Introduces Interim Analysis in the Ongoing Allob Phase IIB Study for High-Risk Tibial Fractures

Medsenic SAS entered into a non-binding term sheet to acquire Bone Therapeutics SA (ENXTBR:BOTHE) in a reverse merger transaction.

Medsenic SAS entered into a non-binding term sheet to acquire Bone Therapeutics SA (ENXTBR:BOTHE) in a reverse merger transaction.

Medsenic SAS entered into a non-binding term sheet to acquire Bone Therapeutics SA (ENXTBR:BOTHE).

Full year 2021 earnings released: €0.77 loss per share (vs €1.35 loss in FY 2020)

Price target decreased to €2.50

High number of new and inexperienced directors

Bone Therapeutics SA announced that it expects to receive €5 million in funding from Abo-Security Srl

Bone Therapeutics SA announced that it expects to receive €5 million in funding from Abo-Security Srl

High number of new and inexperienced directors

Bone Therapeutics Publishes Results of ALLOB Phase I/IIa study for the treatment of delayed-union fractures in Stem Cell Research & Therapy

Is Bone Therapeutics (EBR:BOTHE) A Risky Investment?

Price target increased to €5.50

Bone Therapeutics SA to Report First Half, 2021 Results on Sep 08, 2021

Bone Therapeutics and Rigenerand SRL SignS Partnership for Cell Therapy Process Development

Bone Therapeutics Treats First Patient in Allob Phase IIb Tibial Fracture Study

Bone Therapeutics Completes Recruitment and Patient Treatment in JTA-004 Pivotal Phase III Knee Osteoarthritis Study

Price target lowered to €4.75

What Type Of Returns Would Bone Therapeutics'(EBR:BOTHE) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

New 90-day high: €3.40

Catalent Pharma Solutions, Inc. completed the acquisition of Skeletal Cell Therapy Support SA from Bone Therapeutics SA (ENXTBR:BOTHE).

Bone Therapeutics Announces the Start of a New Research Collaboration with Expert Industry and Academic Partners

Catalent Pharma Solutions, Inc. signed share purchase agreement to acquire Skeletal Cell Therapy Support SA from Bone Therapeutics SA (ENXTBR:BOTHE) for €12 million.

Bone Therapeutics Sa and Catalent Pharma Solutions, Inc. Sign Agreements to Streamline Production of the Allogeneic Cell Therapy Product, Allob

Bone Therapeutics Reaches 50% Treated Patients in Ongoing JTA-004 Phase III Pivotal Knee Osteoarthritis Study

Bone Therapeutics Allogeneic Cell Therapy Product, ALLOB, Shows 90% Fusion Rate at 24 Months in Phase IIa Study in Lumbar Spinal Fusion

Bone Therapeutics, Link Health Pharma Co., Ltd and Shenzhen Pregene Biopharma Co., Ltd. to Develop and Commercialize the ALLOB Allogeneic Bone Cell Therapy Platform in China and Southeast Asia

New 90-day low: €2.14

Bone Therapeutics SA announced that it has received funding from Société Régionale d'Investissement de Wallonie S.A.

Earnings released

New 90-day low - €2.17

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age